Drugs / Enlicitide
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT07619443 | Jul → Sep 2026 expected | — | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT07481708 | Mar → May 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07300280 | Dec 2025 → Oct 2026 expected | — | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT07044479 | Jul → Aug 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06880874 | Apr → May 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06719544 | Jan 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06643377 | Nov 2024 → Jun 2025 | impaired renal function disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06609512 | Oct 2024 → Jan 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06597760 | Oct → Nov 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06575959 | Sep 2024 → May 2025 | liver disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06658626 | Mar → Aug 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06814106 | Mar → May 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06655311 | Sep 2022 → Jan 2024 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05070390 | Nov 2021 → May 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07614984 | Jun 2026 → Oct 2027 expected | lipoprotein, variant of beta | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07216482 | Nov 2025 → Dec 2026 expected | hyperlipidemia | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06450366 | Jul 2024 → Feb 2025 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05952869 | Aug 2023 → Apr 2025 | familial hypercholesterolemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enlicitide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07614984 ↗ |
| Known as | Enlicitide Chloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06655311 ↗ |
| Known as | MK-0616 | “A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)” NCT06655311 ↗1“enlicitide (MK-0616)” NCT07481708 ↗ |
| Action | Inhibit | “an oral proprotein convertase subtilisin/kexin type 9 inhibitor” PMID 41206969 ↗ Jan 2026 |
| Route | Oral | “Participants received 20 mg of enlicitide decanoate orally once daily (QD) for up to 52 weeks.” NCT05952869 ↗ |
| Target | PCSK9 | “an oral proprotein convertase subtilisin/kexin type 9 inhibitor” PMID 41206969 ↗ Jan 2026 |